• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Schechter Jonathan

    10/17/25 5:11:11 PM ET
    $TAOX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TAOX alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    SCHECHTER JONATHAN

    (Last) (First) (Middle)
    C/O TAO SYNERGIES INC.
    1185 AVENUE OF THE AMERICAS, 3RD FLOOR

    (Street)
    NEW YORK NY 10036

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    TAO Synergies Inc. [ TAOX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    08/06/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Employee Stock Option (right to buy) $10.38 08/06/2025(1) A 10,000 07/14/2026 07/14/2035 Common Stock 10,000 $0 10,000 D
    Explanation of Responses:
    1. The option grant was approved by a committee of TAO Synergies Inc.'s (the "Issuer") board of directors on July 14, 2025 subject to shareholder approval of an amendment to the Issuer's 2020 Equity Incentive Plan (the "Plan") to increase the number of shares authorized for issuance of awards under the Plan. The Issuer received shareholder approval of the amendment to the Plan on August 6, 2025.
    /s/ Robert Weinstein, Attorney-in-fact 10/17/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $TAOX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TAOX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $TAOX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    TAO Synergies and Yuma Asset Management to Host Livestream on X: Bittensor (TAO) and DeAI Innovation

    November 18 at 12:15 p.m. ET—Bittensor expert James Altucher and Yuma CRO Evan Malanga dive deep into TAO, decentralized AI, and network outlook as TAO halving approaches TAO Synergies is the largest publicly traded holder of Bittensor's native TAO token, first public company to invest in blockchain subnets NEW YORK, Nov. 18, 2025 /PRNewswire/ -- TAO Synergies Inc. (NASDAQ:TAOX) ("TAO Synergies" or the "Company"), a digital asset treasury company focused on Bittensor (TAO), the premier crypto token for decentralized artificial intelligence (DeAI), today announced that it will partner with Yuma to participate in a Yuma Asset Management Investor Spotlight, an X Livestream event today, Tuesday

    11/18/25 9:15:00 AM ET
    $TAOX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TAO Synergies Announces Initial $750,000 Investment in Yuma Asset Management's Subnet Funds

    Seeks to optimize returns for shareholders while fostering evolution of Bittensor's decentralized machine intelligence marketplace NEW YORK, Nov. 4, 2025 /PRNewswire/ -- TAO Synergies Inc. (NASDAQ:TAOX) ("TAO Synergies" or the "Company"), a digital asset treasury company focused on Bittensor (TAO), the premier crypto token for decentralized artificial intelligence (DeAI), today announced an initial $750,000 investment in Yuma Asset Management's Bittensor Subnet Funds, enhancing the Company's exposure to subnets in the Bittensor ecosystem. These positions demonstrate TAO Synergies' commitment to decentralized AI, the Bittensor / TAO crypto token, and subnet tokens that will ultimately drive t

    11/4/25 9:15:00 AM ET
    $TAOX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TAO Synergies Raises Bittensor (TAO) Holdings to over 54,000 Tokens, Largest Publicly Traded Holder of Top Decentralized AI Cryptocurrency

    NEW YORK, Oct. 20, 2025 /PRNewswire/ -- TAO Synergies Inc. (NASDAQ:TAOX) ("TAO Synergies" or the "Company"), a digital asset treasury company focused on Bittensor (TAO), the premier crypto token for decentralized artificial intelligence (DeAI), today announced that through acquisition and staking, the Company's total TAO holdings have increased to 54,058 tokens. This further solidifies TAO Synergies' position as the largest publicly traded pure-play holder of Bittensor (TAO), the groundbreaking protocol powering decentralized AI innovation. TAO Synergies continues to execute on its mission to democratize access to decentralized AI for retail and institutional investors alike, while capturin

    10/20/25 9:15:00 AM ET
    $TAOX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TAOX
    SEC Filings

    View All

    SEC Form DEF 14A filed by Tao Synergies Inc.

    DEF 14A - TAO Synergies Inc. (0001571934) (Filer)

    11/17/25 4:50:47 PM ET
    $TAOX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Tao Synergies Inc.

    10-Q - TAO Synergies Inc. (0001571934) (Filer)

    11/14/25 4:18:43 PM ET
    $TAOX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3 filed by Tao Synergies Inc.

    S-3 - TAO Synergies Inc. (0001571934) (Filer)

    11/12/25 4:10:46 PM ET
    $TAOX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TAOX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Weinstein Robert covered exercise/tax liability with 4,000 shares and was granted 10,000 shares, increasing direct ownership by 57% to 16,574 units (SEC Form 4)

    4 - TAO Synergies Inc. (0001571934) (Issuer)

    10/17/25 5:14:09 PM ET
    $TAOX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Singer William S. was granted 15,000 shares and covered exercise/tax liability with 6,000 shares, increasing direct ownership by 85% to 19,566 units (SEC Form 4)

    4 - TAO Synergies Inc. (0001571934) (Issuer)

    10/17/25 5:13:16 PM ET
    $TAOX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Executive Chairman Silverman Joshua was granted 100,000 shares and covered exercise/tax liability with 40,000 shares, increasing direct ownership by 225% to 86,681 units (SEC Form 4)

    4 - TAO Synergies Inc. (0001571934) (Issuer)

    10/17/25 5:12:16 PM ET
    $TAOX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TAOX
    Financials

    Live finance-specific insights

    View All

    TAO Synergies Acquires $10 Million of Bittensor (TAO) to Become Largest Publicly Traded Pure Play TAO Holder

    29,899 TAO tokens purchased to date Stakes tokens in decentralized AI network for yield generation NEW YORK, July 17, 2025 /PRNewswire/ -- TAO Synergies Inc. (NASDAQ:TAOX) (the "Company"), a digital asset treasury company focused on Bittensor (TAO), the premier crypto token for decentralized artificial intelligence (AI), today announced that as of July 17, 2025, it has acquired 29,899 TAO tokens for a total purchase price of $10.0 million, at an average price of approximately $334 per token. The purchases of TAO are in accordance with the Company's digital asset treasury strategy directed toward TAO, the native token for Bittensor, a decentralized AI network that incentivizes the development

    7/17/25 9:15:00 AM ET
    $TAOX
    Biotechnology: Pharmaceutical Preparations
    Health Care